Work for Targacept, Inc.?

Claim Your Profile

Targacept, Inc. Logo Image

Targacept, Inc.

Most Recent Annual Report

2014 Form 10K

Targacept, Inc.

Annual
Report

Order Free Hardcopy

You can request a free hardcopy of this report mailed to you by clicking the button below.

Add Annual Report

Archive

  • Targacept, Inc.
  • Targacept, Inc.
  • Targacept, Inc.
  • Show 1 more archive
  • Targacept, Inc.

About Targacept, Inc.

Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder.

Ticker:
TRGT
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?